Pharsight

Suboxone generic

Suboxone is an anti-opioid addiction drug owned by Indivior Inc. The active ingredient in Suboxone, Buprenorphine Hydrochloride and Naloxone Hydrochloride, collectively contribute to its effectiveness. Suboxone was first authorized for market use on August 30, 2010, and has a total of 8 drug patents, 4 of which have expired.

When will Suboxone generic be available?

Suboxone generics will potentially be available after March 26, 2030, once the last patent (US8475832) expires. Despite the earlier patents, the generic release date corresponds to the last patent's expiration due to Para IV filing.

Suboxone uses

Suboxone is used for the treatment of opioid use disorder. Its active ingredients, Buprenorphine Hydrochloride and Naloxone Hydrochloride, make this drug effective when administered by sublingual route to humans for maintenance treatment of opioid dependence. It is also used for the treatment of opioid dependence via sublingual or buccal application.

Suboxone patent expiration

Suboxone has a number of patents filed with the US Patent Office. The most crucial is US8475832, titled 'Sublingual and buccal film compositions', which is set to expire on March 26, 2030. The expiration of this patent will likely allow the release of Suboxone generics into the market. For more information, below are the details of the patents:

EPO Oppostions filed on Suboxone

Litigations filed on Suboxone

Suboxone dosage

Want to ask something?